Filed with SSE · Stock code 688198 · · 3 pages · Chinese
Beijing Balance Medical Technology Co. Ltd. has announced the voluntary disclosure regarding the entry of its ePTFE pulmonary artery valved conduit into the special review procedure for innovative medical devices. The product is designed for complex congenital heart diseases and aims to address long-standing challenges in pulmonary valve replacement for pediatric patients. The company anticipates that this review process will enhance the efficiency of the registration audit, potentially shortening the product's registration cycle. However, the product's market launch remains uncertain and will depend on regulatory approval.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Announcement on Voluntary Disclosure of Entry of ePTFE Pulmonary Artery Valved Conduit into the Special Review Procedure for Innovative Medical Devices
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Beijing Balance Medical Technology Co. Ltd. on 6ix
Follow Beijing Balance Medical Technology into a list and get an email when it puts out news.
Follow Beijing Balance Medical Technology